The Prevalence and Morbid Consequences Aris- Ing from Untreated Sleep-related Breathing Disorders (srbds) Have Sparked an Enormous

The reader needs to be aware of the following information. On June 27, 2006, Cypress Bioscience Inc. announced “that the results of recently completed Phase IIa trials do not support continuing a development program evaluating combinations of mirtazapine with another approved drug as potential pharmaceutical treatments for obstructive sleep apnea (OSA). Cypress and Organon, the human healthcare business unit of Akzo Nobel, had each independently conducted Phase IIa trials that served as the basis for today’s announcement. A previous independently conducted small preliminary investigator sponsored pilot trial found that mirtazapine was able to reduce the number of abnormal respiratory events over the course of the night by roughly fifty percent. However, those data were not replicated in the recently completed phase IIa trials.” (source: http://www.cypressbio.com/news/releases/20060627.pdf)